Publication Cover
Inhalation Toxicology
International Forum for Respiratory Research
Volume 32, 2020 - Issue 5
682
Views
15
CrossRef citations to date
0
Altmetric
Research Article

Acute neuroradiological, behavioral, and physiological effects of nose-only exposure to vaporized cannabis in C57BL/6 mice

, , , , , ORCID Icon & ORCID Icon show all
Pages 200-217 | Received 26 Nov 2019, Accepted 06 May 2020, Published online: 01 Jun 2020

References

  • Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, Aweeka FT, Benowitz NL, Bredt BM, Kosel B, Aberg JA, et al. 2003. Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Ann Intern Med. 139(4):258–266.
  • Abrams DI, Jay C, Shade SB, Vizoso HP, Reda H, Press S, Kelly M, Rowbotham M, Petersen K. 2007. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology. 68(7):515–521.
  • Abrams DI, Vizoso HP, Shade SB, Jay C, Kelly ME, Benowitz NL. 2007. Vaporization as a smokeless cannabis delivery system: a pilot study. Clin Pharmacol Ther. 82(5):572–578.
  • Adam T, McAughey J, McGrath C, Mocker C, Zimmermann R. 2009. Simultaneous on-line size and chemical analysis of gas phase and particulate phase of cigarette mainstream smoke. Anal Bioanal Chem. 394(4):1193–1203.
  • Adams MD, Earnhardt JT, Dewey WL, Harris LS. 1976. Vasoconstrictor actions of THC in the rat. J Pharmacol Exp Ther. 196(3):649–656.
  • Agrawal A, Lynskey M. 2009. Tobacco and cannabis co-occurrence: does route of administration matter? Drug Alcohol Depend. 99(1-3):240–247.
  • Aizpurua-Olaizola O, Elezgarai I, Rico-Barrio I, Zarandona I, Etxebarria N, Usobiaga A. 2017. Targeting the endocannabinoid system: future therapeutic strategies. Drug Discov Today. 22(1):105–110.
  • Amitoj S, Sahil A, Mark F, Yugandhar M, Sudip N, Jamshid S. 2016. Abstract 14100: marijuana (Cannabis) use is an independent predictor of stress cardiomyopathy in younger men. Circulation. 134:A14100.
  • Anderson PJ, Wilson JD, Hiller FC. 1989. Particle size distribution of mainstream tobacco and marijuana smoke analysis using the electrical aerosol analyzer. Am Rev Respir Dis. 140(1):202–205.
  • Andreasson S, Engstrom A, Allebeck P, Rydberg U. 1987. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet. 330(8574):1483–1486.
  • Anjilvel S, Asgharian B. 1995. A multiple-path model of particle deposition in the rat lung. Toxicol Sci. 28(1):41–50.
  • Asgharian B, Price OT, Oldham MJ, Chen LC, Saunders EL, Gordon T, Mikheev VB, Minard KR, Teeguarden JG. 2014. Computational modeling of nanoscale and microscale particle deposition, retention and dosimetry in the mouse respiratory tract. Inhal Toxicol. 26(14):829–842.
  • Bachs L, Mørland H. 2001. Acute cardiovascular fatalities following cannabis use. Forensic Sci Int. 124(2–3):200–203.
  • Beaconsfield P, Ginsburg J, Rainsbury R. 1972. Marihuana smoking. Cardiovascular effects in man and possible mechanisms. N Engl J Med. 287(5):209–212.
  • Beaulieu P. 2005. Toxic effects of cannabis and cannabinoids: animal data. Pain Res Manag. 10(13):23–26.
  • Benjamini Y, Hochberg Y. 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc. 57(1):289–300.
  • Blaes SL, Orsini CA, Holik HM, Stubbs TD, Ferguson SN, Heshmati SC, Bruner MM, Wall SC, Febo M, Bruijnzeel AW, et al. 2019. Enhancing effects of acute exposure to cannabis smoke on working memory performance. Neurobiol Learn Mem. 157:151–162.
  • Blanco C, Hasin DS, Wall MM, Flórez-Salamanca L, Hoertel N, Wang S, Kerridge BT, Olfson M. 2017. Cannabis use and risk of psychiatric disorders: prospective evidence from a US national longitudinal study. JAMA - J Am Med Assoc. 317(10):1070–1071.
  • Bloomfield MAP, Hindocha C, Green SF, Wall MB, Lees R, Petrilli K, Costello H, Ogunbiyi MO, Bossong MG, Freeman TP. 2019. The neuropsychopharmacology of cannabis: a review of human imaging studies. Pharmacol Ther. 195:132–161.
  • Brevard ME, Duong TQ, King JA, Ferris CF. 2003. Changes in MRI signal intensity during hypercapnic challenge under conscious and anesthetized conditions. Magn Reson Imaging. 21(9):995–1001.
  • Brown DJ, Miller FN, Longnecker DE, Greenwald E, Harris PD, Forney RB. 1974. The influence of THC on cardiovascular and subcutaneous microcirculatory systems in the bat. J Pharmacol Exp Ther. 188(3):624–629.
  • Bruijnzeel AW, Qi X, Guzhva LV, Wall S, Deng JV, Gold MS, Febo M, Setlow B. 2016. Behavioral characterization of the effects of cannabis smoke and anandamide in rats. PLoS One. 11(4):e0153327–24.
  • Burns HD, van Laere K, Krause S, Bormans G, Connolly B, Stoch SA, Ryan C, de Hoon J, Hargreaves RJ, Jewell JP, et al. 2007. 18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc Natl Acad Sci Usa. 104(23):9800–9805.
  • Caverno I, Ertel R, Buckley JP, Jandhyala BS. 1972. Effects of THC on regional blood flow in anesthetized dogs. Eur J Pharmacol. 20(3):373–376.
  • Chakrabarty RK, Moosmüller H, Garro MA, Arnott WP, Walker J, Susott RA, Babbitt RE, Wold CE, Lincoln EN, Hao WM. 2006. Emissions from the laboratory combustion of wildland fuels: particle morphology and size. J Geophys Res. 111(D7):1–16.
  • Cheng TJ, Hwang JS, Wang PY, Tsai CF, Chen CY, Lin SH, Chan CC. 2003. Effects of concentrated ambient particles on heart rate and blood pressure in pulmonary hypertensive rats. Environ Health Perspec. 111(2):147–150.
  • Cohen K, Weizman A, Weinstein A. 2019. Positive and negative effects of cannabis and cannabinoids on health. Clin Pharmacol Ther. 105(5):1139–1147.
  • Compton WM, Han B, Jones CM, Blanco C, Hughes A. 2016. Marijuana use and use disorders in adults in the USA, 2002–14: analysis of annual cross-sectional surveys. The Lancet Psychiatry. 3(10):954–964.
  • Cone EJ. 1990. Marijuana effects and urinalysis after passive inhalation and oral ingestion. NIDA Res Monogr. 99:88–96.
  • Dannon P, Lowengrub K, Amiaz R, Grunhaus L, Kotler M. 2004. Comorbid cannabis use and panic disorder: short term and long term follow-up study. Hum Psychopharmacol. 19(2):97–101.
  • Dove Pettit DA, Harrison MP, Olson JM, Spencer RF, Cabral GA. 1998. Immunohistochemical localization of the neural cannabinoid receptor in rat brain. J Neurosci Res. 51(3):391–402.
  • ElSohly MA, Radwan MM, Gul W, Chandra S, Galal A. 2017. Phytochemistry of Cannabis sativa L. Prog Chem Org Nat Prod. 103:1–36.
  • Fant RV, Heishman SJ, Bunker E, Pickworth WB. 1998. Acute and residual effects of marijuana in humans. Pharmacol Biochem Behav. 60(4):777–784.
  • Ferris CF, Kulkarni P, Toddes S, Yee J, Kenkel W, Nedelman M. 2014. Studies on the Q175 knock-in model of Huntington’s disease using functional imaging in awake mice: evidence of olfactory dysfunction. Front Neurol. 5(94):94–14.
  • Fowles J, Dybing E. 2003. Application of toxicological risk assessment principles to the chemical constituents of cigarette smoke. Tobacco Control. 12(4):424–431.
  • Franz CA, Frishman WH. 2016. Marijuana use and cardiovascular disease. Cardiol Rev. 24(4):158–162.
  • Freeman TP, Pope RA, Wall MB, Bisby JA, Luijten M, Hindocha C, Mokrysz C, Lawn W, Moss A, Bloomfield MAP, et al. 2018. Cannabis dampens the effects of music in brain regions sensitive to reward and emotion. Int J Neuropsychopharmacol. 21(1):21–32.
  • Fried PA, Nieman GW. 1973. Inhalation of cannabis smoke in rats. Pharmacol Biochem Behav. 1(4):371–378.
  • Genovese CR, Lazar NA, Nichols T. 2002. Thresholding of statistical maps in functional neuroimaging using the false discovery rate. Neuroimage. 15(4):870–878.
  • Gieringer D, St. Laurent J, Goodrich S. 2004. Cannabis vaporizer combines efficient delivery of THC with effective suppression of pyrolytic compounds. J Cannabis Ther. 4(1):7–26.
  • Goyal H, Awad HH, Ghali JK. 2017. Role of cannabis in cardiovascular disorders. J Thorac Dis. 9(7):2079–2092.
  • Goyal H, Singla U, Gupta U, May E. 2017. Role of cannabis in digestive disorders. Eur J Gastroenterol Hepatol. 29(2):135–143.
  • Grotenhermen F. 2003. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 42(4):327–360.
  • Ha MA, Smith GJ, Cichocki JA, Fan L, Liu YS, Caceres AI, Jordt SE, Morris JB. 2015. Menthol attenuates respiratory irritation and elevates blood cotinine in cigarette smoke exposed mice. PLoS One. 10(2):e0117128–16.
  • Hancox R, Poulton R, Ely M, Welch D, Taylor D, McLachlan C, Greene J, Moffitt T, Caspi A, Sears M. 2010. Effects of cannabis on lung function: a population-based cohort study. Eur Respir J. 35(1):42–47.
  • Harder S, Rietbrock S. 1997. Concentration-effect relationship of THC and prediction of psychotropic effects after smoking marijuana. Int J Clin Pharmacol Ther. 35(4):155–159.
  • Hasin DS. 2018. US epidemiology of cannabis use and associated problems. Neuropsychopharmacology. 43(1):195–212.
  • Hazekamp A, Ruhaak R, Zuurman L, van Gerven J, Verpoorte R. 2005. Evaluation of a vaporizing device (volcano) for the pulmonary administration of tetrahydrocannabinol. Int J Drug Dev Res. 3(2):26–33.
  • Hedden SL, Kennet J, Lipari R, Medley G, Tice P, Copello EAP. Kroutil LA 2015. Behavioral health trends in the United States: results from the 2014 National Survey on Drug Use and Health. SAMHSA.
  • Helyes Z, Kemény Á, Csekő K, Szőke É, Elekes K, Mester M, Sándor K, Perkecz A, Kereskai L, Márk L. 2017. Marijuana smoke induces severe pulmonary hyperresponsiveness, inflammation, and emphysema in a predictive mouse model not via CB1 receptor activation. Am J Physiol - Lung Cell Mol Physiol. 313(2):267–277.
  • Hiller FC, Wilson FJ, Mazumder MK, Wilson JD, Bone RC. 1984. Concentration and particle size distribution in smoke from marijuana cigarettes with different THC content. Fundam Appl Toxicol. 4(3 Pt 1):451–454.
  • Hinds WC. 1999. Aerosol technology: properties, behavior, and measurement of airborne particles. 2nd ed. New York (NY): John Wiley and Sons.
  • Horwood LJ, Fergusson DM, Coffey C, Patton GC, Tait R, Smart D, Letcher P, Silins E, Hutchinson DM. 2012. Cannabis and depression: an integrative data analysis of four Australasian cohorts. Drug Alcohol Depend. 126(3):369–378.
  • Hosseini S, Li Q, Cocker D, Weise D, Miller A, Shrivastava M, Miller JW, Mahalingam S, Princevac M, Jung H. 2010. Particle size distributions from laboratory-scale biomass fires using fast response instruments. Atmos Chem Phys. 10(16):8065–8076.
  • Huestis MA, Sampson AH, Holicky BJ, Henningfield JE, Cone EJ. 1992. Characterization of the absorption phase of marijuana smoking. Clin Pharmacol Ther. 52(1):31–41.
  • Huestis MA. 2007. Human cannabinoid pharmacokinetics. Chem Biodivers. 4(8):1770–1804.
  • Ingebrethsen BJ, Cole SK, Alderman SL. 2012. Electronic cigarette aerosol particle size distribution measurements. Inhal Toxicol. 24(14):976–984.
  • Jackson Laboratory. 2018. Body weight information for C57BL/6J. [October 2018]. https://www.jax.org/jax-mice-and-services/strain-data-sheet-pages/body-weight-chart-000664#.
  • Jacobson MR, Watts JJ, Boileau I, Tong J, Mizrahi R. 2019. A systematic review of phytocannabinoid exposure on the endocannabinoid system: implications for psychosis. Eur Neuropsychopharmacol. 29(3):330–348.
  • Johnson-Sasso CP, Tompkins C, Kao DP, Walker LA. 2018. Marijuana use and short-term outcomes in patients hospitalized for acute myocardial infarction. PLoS One. 13(7):e0199705–12.
  • Kamal AS, Rohr AC, Mukherjee B, Morishita M, Keeler GJ, Harkema JR, Wagner JG. 2011. PM2.5-induced changes in cardiac function of hypertensive rats depend on wind direction and specific sources in Steubenville, Ohio. Inhal Toxicol. 23(7):417–430.
  • Kane DB, Asgharian B, Price OT, Rostami A, Oldham MJ. 2010. Effect of smoking parameters on the particle size distribution and predicted airway deposition of mainstream cigarette smoke. Inhal Toxicol. 22(3):199–209.
  • Kasten CR, Zhang Y, Boehm SL. 2019. Acute cannabinoids produce robust anxiety-like and locomotor effects in mice, but long-term consequences are age- and sex-dependent. Front Behav Neurosci. 13:32–1–18.
  • Kaushik M, Alla VM, Madan R, Arouni AJ, Mohiuddin SM. 2011. Recurrent stress cardiomyopathy with variable regional involvement: insights into etiopathogenetic mechanisms. Circulation. 124(22):556–557.
  • King JA, Garelick TS, Brevard ME, Chen W, Messenger TL, Duong TQ, Ferris CF. 2005. Procedure for minimizing stress for fMRI studies in conscious rats. J Neurosci Methods. 148(2):154–160.
  • Koppel BS, Brust JCM, Fife T, Bronstein J, Youssof S, Gronseth G, Gloss D. 2014. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 82(17):1556–1563.
  • Lankenau SE, Fedorova EV, Reed M, Schrager SM, Iverson E, Wong CF. 2017. Marijuana practices and patterns of use among young adult medical marijuana patients and non-patient marijuana users. Drug Alcohol Depend. 170:181–188.
  • Lanz C, Mattsson J, Soydaner U, Brenneisen R. 2016. Medicinal cannabis: in vitro validation of vaporizers for the smoke-free inhalation of cannabis. PLoS One. 11(1):e0147286–18.
  • Lichtman AH, Martin BR, Poklis A, Bridgen DT, Wilson DM, Poklis JL, Byron PR, Razdan RK, Meng Y, Peart J. 2000. Pharmacological evaluation of aerosolized cannabinoids in mice. Eur J Pharmacol. 399(2-3):141–149.
  • Lichtman AH, Poklis JL, Poklis A, Wilson DM, Martin BR. 2001. The pharmacological activity of inhalation exposure to marijuana smoke in mice. Drug Alcohol Depend. 63(2):107–116.
  • Machado Rocha FC, Stéfano SC, De Cássia Haiek R, Rosa Oliveira LMQ, Da Silveira DX. 2008. Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. Eur J Cancer Care (Engl). 17(5):431–443.
  • Maertens RM, White PA, Williams A, Yauk CL. 2013. A global toxicogenomic analysis investigating the mechanistic differences between tobacco and marijuana smoke condensates in vitro. Toxicology. 308:60–73.
  • Manwell LA, Charchoglyan A, Brewer D, Matthews BA, Heipel H, Mallet PE. 2014. A vapourized Δ(9)-tetrahydrocannabinol (Δ(9)-THC) delivery system part I: development and validation of a pulmonary cannabinoid route of exposure for experimental pharmacology studies in rodents. J Pharmacol Toxicol Methods. 70(1):120–127.
  • Manwell LA, Ford B, Matthews BA, Heipel H, Mallet PE. 2014. A vapourized Δ(9)-tetrahydrocannabinol (Δ(9)-THC) delivery system part II: comparison of behavioural effects of pulmonary versus parenteral cannabinoid exposure in rodents. J Pharmacol Toxicol Methods. 70(1):112–119.
  • Marshell R, Kearney-Ramos T, Brents LK, Hyatt WS, Tai S, Prather PL, Fantegrossi WE. 2014. In vivo effects of synthetic cannabinoids JWH-018 and JWH-073 and phytocannabinoid Δ9-THC in mice: inhalation versus intraperitoneal injection. Pharmacol Biochem Behav. 124:40–47.
  • Martin AR, Finlay WH. 2015. Nebulizers for drug delivery to the lungs. Expert Opin Drug Deliv. 12(6):889–900.
  • McGrath C, Warren N, Biggs P, McAughey J. 2009. Real-time measurement of inhaled and exhaled cigarette smoke: implications for dose. J Phys Conf Ser. 151:1–6.
  • McRitchie RJ, White SW. 1974. Role of the trigeminal, olfactory, carotid sinus and aortic nerves in the respiratory and circulatory response to nasal inhalation of cigarette smoke and other irritants in the rabbit. Aust J Expo Biol Med Sci. 52(1):57.
  • Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RSE, McDonald K, Ward A, Poulton R, Moffitt TE. 2012. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci. 109(40):2657–2664.
  • Méndez LB, Gookin G, Phalen RF. 2010. Inhaled aerosol particle dosimetry in mice: a review. Inhal Toxicol. 22(sup2):15–20.
  • Miller FJ, Asgharian B, Schroeter JD, Price O. 2016. Improvements and additions to the Multiple Path Particle Dosimetry model. J Aerosol Sci. 99:14–26.
  • Milzoff RJ, Forney RB. 1971. The cardiovascular effects of Δ 9-THC in vagotomized rats. Pharmacologist. 13:247.
  • Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE. 2001. Triggering myocardial infarction by marijuana. Circulation. 103(23):2805–2809.
  • Moore BA, Augustson EM, Moser RP, Budney AJ. 2005. Respiratory effects of marijuana and tobacco use in a U.S. sample. J Gen Intern Med. 20(1):33–37.
  • Morales P, Hurst DP, Reggio PH. 2017. Molecular targets of the phytocannabinoids: a complex picture. Prog Chem Org Nat Prod. 103:103–131.
  • Morean ME, Kong G, Camenga DR, Cavallo DA, Krishnan-Sarin S. 2015. High school students' use of electronic cigarettes to vaporize cannabis. Pediatrics. 136(4):611–616.
  • Newmeyer MN, Swortwood MJ, Barnes AJ, Abulseoud OA, Scheidweiler KB, Huestis MA. 2016. Free and glucuronide whole blood cannabinoids’ pharmacokinetics after controlled smoked, vaporized, and oral cannabis administration in frequent and occasional cannabis users: identification of recent cannabis intake. Clin Chem. 62(12):1579–1592.
  • Obot CJ, Lee KM, Fuciarelli AF, Renne RA, McKinney WJ. 2004. Characterization of mainstream cigarette smoke-induced biomarker responses in ICR and C57BI/6 mice. Inhal Toxicol. 16(10):701–719.
  • Oldham MJ, Phalen RF, Schum GM, Daniels DS. 1994. Predicted nasal and tracheobronchial particle deposition efficiencies for the mouse. Ann. Occ. Hyg. 8(inhaled particles VII):135–141.
  • Owen KP, Sutter ME, Albertson TE. 2014. Marijuana: respiratory tract effects. Clin Rev Allergy Immunol. 46(1):65–81.
  • Pacher P, Mukhopadhyay P, Mohanraj R, Godlewski G, Bátkai S, Kunos G. 2008. Modulation of the endocannabinoid system in cardiovascular disease: therapeutic potential and limitations. Hypertension. 52(4):601–607.
  • Pacher P, Steffens S, Haskó G, Schindler TH, Kunos G. 2018. Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly. Nat Rev Cardiol. 15(3):151–166.
  • Patel S, Hill MN, Cheer JF, Wotjak CT, Holmes A. 2017. The endocannabinoid system as a target for novel anxiolytic drugs. Neurosci Biobehav Rev. 76(Pt A):56–66.
  • Patskan G, Reininghaus W. 2003. Toxicological evaluation of an electrically heated cigarette. Part 1: overview of technical concepts and summary of findings. J Appl Toxicol. 23(5):323–328.
  • Patton GC, Coffey C, Carlin JB, Degenhardt L, Lynskey M, Hall W. 2002. Cannabis use and mental health in young people: cohort study. BMJ. 325(7374):1195–1198.
  • Perez-Reyes M. 1990. Marijuana smoking: factors that influence the bioavailability of tetrahydrocannabinol. NIDA Res Monogr. 99:42–62.
  • Pertwee RG. 2010. Pharmacological actions of cannabinoids. Handb Exp Pharmacol. 168:S205.
  • Philpot LM, Ebbert JO, Hurt RT. 2019. A survey of the attitudes, beliefs and knowledge about medical cannabis among primary care providers. BMC Fam Pract. 20(1):17.
  • Piano MR. 2017. Cannabis smoking and cardiovascular health: it’s complicated. Clin Pharmacol Ther. 102(2):191–193.
  • Radwan MM, ElSohly MA, El-Alfy AT, Ahmed SA, Slade D, Husni AS, Manly SP, Wilson L, Seale S, Cutler SJ, et al. 2015. Isolation and pharmacological evaluation of minor cannabinoids from high-potency Cannabis sativa. J Nat Prod. 78(6):1271–1276.
  • Ramaekers JG, Kauert G, Theunissen EL, Toennes SW, Moeller MR. 2009. Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. J Psychopharmacol (Oxford). 23(3):266–277.
  • Ribeiro LIG, Ind PW. 2016. Effect of cannabis smoking on lung function and respiratory symptoms: a structured literature review. NPJ Prim Care Respir Med. 26:1–8.
  • Ribeiro LIG, Ind PW. 2018. Marijuana and the lung: hysteria or cause for concern? Breathe (Sheff). 14(3):196–205.
  • Rodgman A, Perfetti T. 2013. The chemical components of tobacco and tobacco smoke. Boca Raton (FL): CRC Press.
  • Rosenkrantz H, Braude MC. 1974. Acute, subacute and 23-day chronic marihuana inhalation toxicities in the rat. Toxicol Appl Pharmacol. 28(3):428–441.
  • Russell C, Rueda S, Room R, Tyndall M, Fischer B. 2018. Routes of administration for cannabis use - basic prevalence and related health outcomes: a scoping review and synthesis. Int J Drug Policy. 52:87–96.
  • Rusznák K, Csekő K, Varga Z, Csabai D, Bóna Á, Mayer M, Kozma Z, Helyes Z, Czéh B. 2018. Long-term stress and concomitant marijuana smoke exposure affect physiology, behavior and adult hippocampal neurogenesis. Front Pharmacol. 9(786):786–720.
  • Sachs J, McGlade E, Yurgelun-Todd D. 2015. Safety and toxicology of cannabinoids. Neurotherapeutics. 12(4):735–746.
  • Schwin R, Goodwin DW, Hill SY. 1973. Marihuana and tidal volume. JAMA. 223(2):194–195.
  • Seibenhener ML, Wooten MC. 2015. Use of the open field maze to measure locomotor and anxiety-like behavior in mice. J Vis Exp. 52434(96):1–6.
  • Sheehan TJ, Hamnett HJ, Beasley R, Fitzmaurice PS. 2018. Chemical and physical variations of cannabis smoke from a variety of cannabis samples in New Zealand. Forensic Sci Res. 1790:1–11.
  • Shiplo S, Asbridge M, Leatherdale ST, Hammond D. 2016. Medical cannabis use in Canada: vapourization and modes of delivery. Harm Reduct J. 13(1):1–10.
  • Shu J, Li D, Ouyang H, Huang J, Long Z, Liang Z, Chen Y, Chen Y, Zheng Q, Kuang M. 2017. Comparison and evaluation of two different methods to establish the cigarette smoke exposure mouse model of. COPD Sci Rep. 7(1):1–11.
  • Singh A, Saluja S, Kumar A, Agrawal S, Thind M, Nanda S, Shirani J. 2018. Cardiovascular complications of marijuana and related substances: a review. Cardiol Ther. 7(1):45–59.
  • Solowij N. 2018. Peering through the haze of smoked vs vaporized cannabis—to vape or not to vape? JAMA Netw Open. 1(7):1–3.
  • Spindle TR, Cone EJ, Schlienz NJ, Mitchell JM, Bigelow GE, Flegel RHE, Vandrey R. 2018. Acute effects of smoked and vaporized cannabis in healthy adults who infrequently use cannabis. JAMA Netw. 1(7):1–14.
  • Tashkin DP, Gliederer F, Rose J, Chang P, Hui KK, Yu JL, Wu TC. 1991. Effects of varying marijuana smoking profile on deposition of tar and absorption of CO and Delta-9-THC. Pharmacol Biochem Behav. 40(3):651–656.
  • Tashkin DP. 2018. Marijuana and lung disease. Chest. 154(3):653–663.
  • UNDOC. 2017. Fact sheet on statistics and trends in illicit drugs. World Drug Rep. 6:1–16.
  • van der Pol P, Liebregts N, Brunt T, van Amsterdam J, de Graaf R, Korf DJ, van den Brink W, van Laar M. 2014. Cross-sectional and prospective relation of cannabis potency, dosing and smoking behaviour with cannabis dependence: an ecological study. Addiction. 109(7):1101–1109.
  • van Hell HH, Bossong MG, Jager G, Kristo G, van Osch MJP, Zelaya F, Kahn RS, Ramsey NF. 2011. Evidence for involvement of the insula in the psychotropic effects of THC in humans: a double-blind, randomized pharmacological MRI study. Int J Neuropsychopharmacol. 14(10):1377–1388.
  • Varvel SA, Bridgen DT, Tao Q, Thomas BF, Martin BR, Lichtman AH. 2005. Delta9-tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice. J Pharmacol Exp Ther. 314(1):329–337.
  • Volkow N, Baler RD, Compton WM, Weiss S. 2014. Adverse health effects of marijuana use. N Engl J Med. 370(23):2219–2227.
  • Vollmer RR, Cavero I, Ertel RJ, Solomon TA, Buckley JP. 1974. Role of the central autonomic nervous system in the hypotension and bradycardia induced by (-)-delta 9-trans-tetrahydrocannabinol. J Pharm Pharmacol. 26(3):186–192.
  • Wagner JG, Allen K, Yang H-y, Nan B, Morishita M, Mukherjee B, Dvonch JT, Spino C, Fink GD, Rajagopalan S, et al. 2014. Cardiovascular depression in rats exposed to inhaled particulate matter and ozone: effects of diet-induced metabolic syndrome. Environ Health Perspect. 122(1):27–33.
  • Watkinson WP, Campen MJ, Wichers LB, Nolan JP, Costa DL. 2003. Cardiac and thermoregulatory responses to inhaled pollutants in healthy and compromised rodents: modulation via interaction with environmental factors. Environ Res. 92(1):35–47.
  • Weinberg AD, Dimen EM, Borzelleca JF, Harris LS. 1977. Weight and activity in male mice after daily inhalation of cannabis smoke in an automated smoke exposure chamber. J Pharm Pharmacol. 29(8):477–481.
  • Weinberg AD, Dimen EM, Simon GS, Harris LS, Borzelleca JF. 1977. Measurements of weight and activity in male mice following inhalation of cannabis smoke in a controlled smoke exposure chamber. Toxicol Appl Pharmacol. 42(2):301–307.
  • Wilson DM, Peart J, Martin BR, Bridgen DT, Byron PR, Lichtman AH. 2002. Physiochemical and pharmacological characterization of a Delta(9)-THC aerosol generated by a metered dose inhaler. Drug Alcohol Depend. 67(3):259–267.
  • Yeh HC, Schum GM. 1980. Models of human lung airways and their application to inhaled particle deposition. Bull Math Biol. 42(3):461–480.
  • Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. 2002. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ. 325(7374):1199–1195.
  • Zhao J, Pyrgiotakis G, Demokritou P. 2016. Development and characterization of electronic-cigarette exposure generation system (Ecig-EGS) for the physico-chemical and toxicological assessment of electronic cigarette emissions. Inhal Toxicol. 28(14):658–669.
  • Zimmerman N, Godri Pollitt KJ, Jeong CH, Wang JM, Jung T, Cooper JM, Wallace JS, Evans GJ. 2014. Comparison of three nanoparticle sizing instruments: the influence of particle morphology. Atmos Environ. 86:140–147.
  • Zimmerman N, Jeong CH, Wang JM, Ramos M, Wallace JS, Evans GJ. 2015. A source-independent empirical correction procedure for the fast mobility and engine exhaust particle sizers. Atmos Environ. 100:178–184.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.